Dermavant’s senior leadership team consists of accomplished biopharmaceutical executives in medical dermatology. Members of this team have a proven track record of developing and commercializing innovative products that are among the best-known prescription dermatology brands. They possess rich industry knowledge, a passion for science, and a shared commitment to improving patients’ lives.
Todd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnick served as Chief Commercial Officer and President of Aesthetics and Therapeutics at Revance. He previously served in global leadership roles at ZELTIQ Aesthetics prior to the company’s acquisition by Allergan, at Galderma Laboratories where he was president and general manager of North America, and at Alcon Laboratories. He is a member of the board of directors of the Children’s Skin Disease Foundation.
As Chief Financial Officer, Ric Peterson brings over 20 years of successful global financial leadership to Dermavant. He has an outstanding record of developing corporate business and finance strategy, business development to achieve corporate strategic objectives and creating value for pharma and biotech businesses. Mr. Peterson joined Dermavant in March 2018. He has extensive experience in the dermatology space, previously serving as Chief Financial Officer at Sienna Biopharmaceuticals and Novan Therapeutics, two clinical-stage biopharmaceutical companies developing treatments for the field of dermatology.
Prior to that time, Mr. Peterson served as Chief Financial Officer, Executive Vice President and Treasurer of Medicis Pharmaceutical Corporation through the company’s $2.6 billion acquisition in 2012. As Chief Financial Officer of Medicis, he was responsible for financial and business operations, business development and information technology. He received his BS in Accounting from Arizona State University.
Dr. Philip M. Brown has over 25 years of experience leading clinical development programs. Prior to joining Dermavant in January 2019, Dr. Brown served as head of global pharmaceutical development at Galderma. He also has served in other clinical development leadership roles in both public and private biotechnology companies, including senior vice president of clinical development at Lexicon Pharmaceuticals, a publicly-traded biopharmaceutical company. Dr. Brown received his M.D. from Texas Tech University Health Science Center School of Medicine, his J.D. from the University of Texas School of Law, and his B.A. from Hendrix College.
Following a distinguished career in academia and years of experience in the pharmaceutical industry, Dr. Rubenstein joined Dermavant in March 2018 from GlaxoSmithKline Dermatology. At GSK, he built an industry-leading dermatology drug development organization as VP, Discovery and Preclinical Development.
Prior to GSK, Dr. Rubenstein held academic roles at the University of North Carolina at Chapel Hill, most recently serving as the Louis C. Skinner Jr. Distinguished Professor of Dermatology.
Dr. Rubenstein received his A.B. in Molecular Biology from Princeton University and his M.D. and Ph.D. from Duke University School of Medicine. He completed his dermatology residency and postdoctoral fellowship in dermatology and biology at UNC-Chapel Hill.
Chris Van Tuyl is a distinguished business lawyer with extensive experience in multiple corporate and transactional matters. His expertise includes mergers and acquisitions, debt and equity securities offerings, venture capital transactions, SEC reporting, corporate governance, commercial contracting and compliance programs. With more than 18 years of experience, Mr. Van Tuyl has served as legal counsel for clients in a wide range of industries, including pharmaceuticals and healthcare.
Mr. Van Tuyl joined Dermavant in March 2018 from Sacks Tierney P.A., where he was a partner in the firm’s corporate practice group. He previously served as Legal Executive at FIS Global, where he managed strategic acquisitions, as well as securities, governance and organizational matters. Prior to joining FIS, Mr. Van Tuyl served as Corporate Secretary, Chief Compliance Officer, and Associate General Counsel at Rayonier, Inc., where he oversaw key aspects of the company’s multi-billion-dollar spinoff of its chemicals business in 2014. Prior to joining Rayonier, Mr. Van Tuyl served as Associate General Counsel at Medicis Pharmaceutical Corporation through the company’s $2.6 billion acquisition in 2012. From 2000 to 2009, Mr. Van Tuyl was a corporate attorney at Squire Sanders & Dempsey LLP in Phoenix and Clifford Chance LLP in New York. He received his BS in Finance summa cum laude from Arizona State University and his JD from Duke University School of Law.